Trial Profile
A phase I/II study of Bevacizumab combined with Cisplatin and Pemetrexed for Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Sep 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2022 Status changed from recruiting to completed.
- 02 Oct 2013 New trial record